01:12 , Jun 28, 2019 |  BC Extra  |  Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
20:30 , Mar 1, 2019 |  BC Extra  |  Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
19:06 , Jun 1, 2018 |  BC Week In Review  |  Company News

Chinese investors launch HPV JV

Shanghai Institute of Biological Products Co. Ltd. (Shanghai, China), 6 Dimensions Capital and Renxian Bioscience Co. Ltd. launched a JV -- Shanghai Zhicheng Bioscience Co. Ltd. -- to develop quadrivalent HPV vaccines in China. The...
21:21 , May 25, 2018 |  BC Extra  |  Company News

Chinese investors launch HPV JV

Shanghai Institute of Biological Products Co. Ltd. (Shanghai, China), 6 Dimensions Capital and Renxian Bioscience Co. Ltd. launched a JV -- Shanghai Zhicheng Bioscience Co. Ltd. -- to develop quadrivalent HPV vaccines in China. The...
23:31 , Sep 7, 2017 |  BioCentury  |  Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
02:27 , Mar 9, 2016 |  BC Extra  |  Company News

Merck, Sanofi ending European vaccines JV

Merck & Co. Inc. (NYSE:MRK) and the Sanofi Pasteur S.A. vaccines unit of Sanofi (Euronext:SAN; NYSE:SNY) mutually agreed to end their European vaccines joint venture, Sanofi Pasteur MSD. The 50/50 JV was created in 1994....
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Gardasil 9 regulatory update

FDA approved Merck’s Gardasil 9 HPV vaccine for use in males ages 16-26. The recombinant HPV vaccine is already marketed in males ages 9-15 and females ages 9-26 to prevent anal cancer caused by HPV...
08:00 , Nov 19, 2015 |  BC Innovations  |  Product R&D

Bugs against chlamydia

Synthetic biology company Prokarium Ltd. is creating oral vaccines based on a bacterial system that produces a wider range of antigens and fewer side effects than injectables. With its goal to produce the first vaccine...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Gardasil 9 regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began a safety review of human papillomavirus (HPV) vaccines, including Gardasil 9. PRAC will review rare reports of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome to...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Gardasil regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began a safety review of human papillomavirus (HPV) vaccines, including Silgard. PRAC will review rare reports of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome to determine...